Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome.
Lymphocytes
PMNs
Polymorphonuclear neutrophils
Urosepsis
mRNA
sPD-L1
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
25
02
2022
accepted:
04
06
2022
pubmed:
23
6
2022
medline:
28
9
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
Sepsis causes a myriad of immunological reactions that result in life-threatening alterations in the human body. Immunosuppression in sepsis is partly attributed to the programmed death receptor (PD-1) and its associated ligand (PD-L1) via the regulation of lymphocytes and neutrophils. Although the soluble forms of these proteins (i.e., sPD-1 and sPD-L1, respectively) are recognized as possible sepsis biomarkers, their functional implications are yet to be elucidated. Our research assessed the correlation between sPD-1 and sPD-L1 and blood mRNA markers and sepsis outcome. Blood samples of septic patients of urogenital origin versus control patients (both groups: n = 18) were analyzed. Blood serum sPD-1 and sPD-L1 levels were determined using the enzyme-linked immunosorbent assay (ELISA). The whole blood mRNA concentrations of PD-1, PD-L1, neutrophil markers (CEACAM8 and MPO), and T-lymphocyte markers (TCRβ, CD4 and CD8) were determined via reverse transcriptase quantitative PCR (RT-qPCR). sPD-L1 levels were significantly increased in septic patients when compared to the controls, whereas sPD-1 levels were unaltered. Patients with high sPD-L1 levels, as dichotomized to the median, had a significantly shorter survival rate than those with low sPD-L1 levels. The sensitivity/specificity characteristics of sPD-L1 proved significant for sepsis detection. Furthermore, sPD-L1 correlated with the mRNA concentrations of PD-L1, CEACAM, and MPO, as well as major inflammatory markers (C-reactive protein and procalcitonin). However, sPD-L1 negatively correlated with TCRβ, CD4, and CD8 mRNAs. sPD-L1 was found to be significantly increased in septic patients. Notably, sPD-L1 correlated with PD-L1 mRNA and neutrophil markers and was indicative of adverse outcomes.
Identifiants
pubmed: 35732880
doi: 10.1007/s12026-022-09302-y
pii: 10.1007/s12026-022-09302-y
pmc: PMC9499885
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
CD274 protein, human
0
Ligands
0
Procalcitonin
0
Programmed Cell Death 1 Receptor
0
RNA, Messenger
0
Receptors, Death Domain
0
C-Reactive Protein
9007-41-4
RNA-Directed DNA Polymerase
EC 2.7.7.49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
698-707Informations de copyright
© 2022. The Author(s).
Références
Mol Cell Biochem. 2016 Jun;417(1-2):49-56
pubmed: 27160934
PLoS One. 2017 Jul 20;12(7):e0181704
pubmed: 28727802
Inflamm Res. 2022 Jan;71(1):81-91
pubmed: 34841450
Lancet Infect Dis. 2012 Dec;12(12):919-24
pubmed: 23103175
Urol Nefrol (Mosk). 1990 Jul-Aug;(4):9-13
pubmed: 1703366
Front Immunol. 2021 Mar 09;12:607217
pubmed: 33767693
Cell Immunol. 2005 Jun;235(2):109-16
pubmed: 16171790
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Intensive Care Med. 2019 Oct;45(10):1360-1371
pubmed: 31576433
Int J Mol Sci. 2019 Oct 29;20(21):
pubmed: 31671729
Int Immunopharmacol. 2020 Dec;89(Pt B):107087
pubmed: 33075714
J Leukoc Biol. 2010 Aug;88(2):233-40
pubmed: 20483923
Blood. 2021 Sep 2;138(9):806-810
pubmed: 34473230
Scand J Immunol. 2017 Jan;85(1):66-72
pubmed: 27864994
Nat Rev Dis Primers. 2016 Jun 30;2:16045
pubmed: 28117397
Oncoimmunology. 2020 Apr 14;9(1):1744980
pubmed: 32363112
Cell Immunol. 2014 Jul;290(1):72-9
pubmed: 24908630
Crit Care. 2011;15(2):R99
pubmed: 21418617
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Immun Inflamm Dis. 2021 Mar;9(1):310-318
pubmed: 33417300
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care. 2010;14(6):R206
pubmed: 21083886
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Crit Care. 2011;15(1):R70
pubmed: 21349174
Am J Emerg Med. 2018 Jan;36(1):43-48
pubmed: 28716595
Pak J Med Sci. 2020 Jul-Aug;36(5):1011-1014
pubmed: 32704280
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Urolithiasis. 2021 Aug;49(4):367-375
pubmed: 33439298
Crit Care Med. 2003 Jun;31(6):1737-41
pubmed: 12794413
Nat Immunol. 2006 Mar;7(3):227-8
pubmed: 16482167
Nat Rev Nephrol. 2018 Feb;14(2):121-137
pubmed: 29225343
Medicina (Kaunas). 2019 Apr 10;55(4):
pubmed: 30974881
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71
pubmed: 11698646
J Leukoc Biol. 2016 Dec;100(6):1239-1254
pubmed: 27671246
Cancer Immunol Immunother. 2019 Mar;68(3):421-432
pubmed: 30564891
Biochem Biophys Res Commun. 2020 Sep 10;530(1):278-284
pubmed: 32828299
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Shock. 2019 Mar;51(3):289-297
pubmed: 29702526
Anesthesiology. 2015 Apr;122(4):852-63
pubmed: 25437496
Crit Care. 2018 Apr 17;22(1):95
pubmed: 29661225
Blood. 2021 Sep 2;138(9):744-746
pubmed: 34473236
Blood. 2018 Oct 25;132(17):1805-1817
pubmed: 30209121
Nat Immunol. 2007 Mar;8(3):239-45
pubmed: 17304234
PLoS One. 2017 Jan 5;12(1):e0169176
pubmed: 28056053
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6303-8
pubmed: 19332785
Cell J. 2021 Apr;23(1):14-20
pubmed: 33650816
Crit Care. 2016 May 09;20(1):124
pubmed: 27156867
Mol Cell Biochem. 2020 Oct;473(1-2):15-23
pubmed: 32588279